You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 157 No. 6, 24 MARCH 1997 TABLE OF CONTENTS
  Archives
  •  Online Features
  EDITORIAL
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Lessons From the Trials of Hypertension Prevention, Phase II

Energy Intake Is More Important Than Dietary Sodium in the Prevention of Hypertension

Thomas G. Pickering, MD

Arch Intern Med. 1997;157(6):596-597.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

PHASE II of the Trials of Hypertension Prevention (TOHP II), the results of which are reported in this issue,1 is the latest in a series of studies designed to investigate the feasibility of preventing hypertension by nonpharmacological interventions.2-4 The rationale of these studies may be summarized as follows. First, hypertension is approximately 50% environmental in origin, with the most likely modifiable risk factors being body weight and sodium intake. Second, treatment of established hypertension is expensive and does not lower cardiovascular morbidity as much as originally hoped; patients being treated for hypertension remain at a higher risk of cardiovascular disease than patients without hypertension with the same level of blood pressure (BP).5 Third, several analyses of population surveys of cardiovascular risk factors have concluded that reductions in BP as small as 2.0 mm Hg should produce a marked reduction in cardiovascular risk of 6% for coronary heart . . . [Full Text PDF of this Article]


Author Affiliations

Hypertension Center New York Hospital 525 E 68th St New York, NY 10021



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.